The University of Southampton
University of Southampton Institutional Repository

415. Clinical impact of molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised, controlled study

415. Clinical impact of molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised, controlled study
415. Clinical impact of molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised, controlled study
Background: the management of the COVID-19 pandemic is hampered by the long delays associated with laboratory PCR testing. In hospitals this leads to poor patient flow and nosocomial transmission and so rapid, accurate diagnostic tests are urgently required. The aim of this study was to evaluate the clinical impact and real-world diagnostic accuracy of molecular point-of-care testing (mPOCT) for COVID-19 in hospital. Methods: we performed a prospective, interventional, non-randomised, controlled study of mPOCT for COVID-19 in adults presenting to hospital with suspected COVID-19. Patients were tested using the QIAstat-Dx SARS-CoV-2 at the point-of-care with results delivered to clinical and infection control teams. Control patients were tested using the PHE Rdrp reference assay. The Primary outcome measure was time to result and secondary outcome measures included infection control outcomes and measures of diagnostic accuracy. Results: between 20th March and 29th April 2020 500 patients were tested by POCT and 555 controls, who were tested with laboratory PCR, were identified. Overall 33% were positive for SARS-CoV-2. Median time to results with POCT was 1.7 (1.6 to 1.9) hours versus 21.3 (16.0 to 27.9) hours in the control group (difference of 19.6 hours, 95%CI 19.0 to 20.3; p< 0.0001). Median time to arrival in definitive clinical area (COVID-19 positive or negative ward) was 8.0 (6.0 to 15.0) hours in the POCT group versus 28.8 (23.5 to 38.9) hours in the control group, p< 0.0001. Median time to enrolment into other COVID-19 clinical trials was 1.5 (1 to 3) days in the POCT versus 3.0 (2 to 5) days in the control group, p< 0.0001. Sensitivity of the POCT was 99.4% and specificity was 98.3%. The sensitivity of the laboratory PHE reference RdRp assay was 87.2% and specificity was 98.9%. Conclusion: mPOCT was associated with a large reduction in time to results and improvements in infection control measures and patient flow, compared with laboratory PCR. In addition, patients were recruited onto other clinical trials more rapidly with POCT. The QIAstat-Dx SARS-CoV-2 panel had high diagnostic accuracy for the detection of COVID-19 compared to laboratory PCR. Resources should be urgently made available to support the widespread implementation of mPOCT in hospitals, in preparation for the second wave. Disclosures: Tristan William. Clark, BM MRCP DTM&H MD, BioFire Diagnostics (Other Financial or Material Support, Equiptment and consumables for the purposes of research)BioMerieux (Other Financial or Material Support, Equipment and consumables for the purposes of research)Qiagen (Other Financial or Material Support, Discounted Equipment and consumables for the purposes of research)
S275-S276
Brendish, Nathan J
d07b588f-4919-456d-8604-04efde7711fd
Poole, Stephen
440d7904-ab72-469c-892b-c910cd1cb19b
Naidu, Vasanth V
df9bd215-344a-43b6-b568-60c783353fa9
Mansbridge, Christopher
14001c1f-03fb-49e3-94c7-02fc9dc6bec9
Norton, Nicholas
14bdade9-e59d-4b4a-a87f-ddb74d86d725
Wheeler, Helen
9ec21ee3-2e24-40c7-b342-64a2c371ef7a
Presland, Laura
f9595a32-b871-4d73-8444-dd0fffc08592
Ewings, Sean
326656df-c0f0-44a1-b64f-8fe9578ca18a
Kidd, Stephen P
1409c55c-35d2-4a0b-8ef2-2370e6bf1dee
Cortes, Nick
72b7c08e-d1bf-40f9-823f-29bb907aeec8
Clark, Tristan William
712ec18e-613c-45df-a013-c8a22834e14f
Brendish, Nathan J
d07b588f-4919-456d-8604-04efde7711fd
Poole, Stephen
440d7904-ab72-469c-892b-c910cd1cb19b
Naidu, Vasanth V
df9bd215-344a-43b6-b568-60c783353fa9
Mansbridge, Christopher
14001c1f-03fb-49e3-94c7-02fc9dc6bec9
Norton, Nicholas
14bdade9-e59d-4b4a-a87f-ddb74d86d725
Wheeler, Helen
9ec21ee3-2e24-40c7-b342-64a2c371ef7a
Presland, Laura
f9595a32-b871-4d73-8444-dd0fffc08592
Ewings, Sean
326656df-c0f0-44a1-b64f-8fe9578ca18a
Kidd, Stephen P
1409c55c-35d2-4a0b-8ef2-2370e6bf1dee
Cortes, Nick
72b7c08e-d1bf-40f9-823f-29bb907aeec8
Clark, Tristan William
712ec18e-613c-45df-a013-c8a22834e14f

Brendish, Nathan J, Poole, Stephen, Naidu, Vasanth V, Mansbridge, Christopher, Norton, Nicholas, Wheeler, Helen, Presland, Laura, Ewings, Sean, Kidd, Stephen P, Cortes, Nick and Clark, Tristan William (2020) 415. Clinical impact of molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised, controlled study. Open Forum Infectious Diseases, 7 (Supplement_1), S275-S276. (doi:10.1093/ofid/ofaa439.609).

Record type: Article

Abstract

Background: the management of the COVID-19 pandemic is hampered by the long delays associated with laboratory PCR testing. In hospitals this leads to poor patient flow and nosocomial transmission and so rapid, accurate diagnostic tests are urgently required. The aim of this study was to evaluate the clinical impact and real-world diagnostic accuracy of molecular point-of-care testing (mPOCT) for COVID-19 in hospital. Methods: we performed a prospective, interventional, non-randomised, controlled study of mPOCT for COVID-19 in adults presenting to hospital with suspected COVID-19. Patients were tested using the QIAstat-Dx SARS-CoV-2 at the point-of-care with results delivered to clinical and infection control teams. Control patients were tested using the PHE Rdrp reference assay. The Primary outcome measure was time to result and secondary outcome measures included infection control outcomes and measures of diagnostic accuracy. Results: between 20th March and 29th April 2020 500 patients were tested by POCT and 555 controls, who were tested with laboratory PCR, were identified. Overall 33% were positive for SARS-CoV-2. Median time to results with POCT was 1.7 (1.6 to 1.9) hours versus 21.3 (16.0 to 27.9) hours in the control group (difference of 19.6 hours, 95%CI 19.0 to 20.3; p< 0.0001). Median time to arrival in definitive clinical area (COVID-19 positive or negative ward) was 8.0 (6.0 to 15.0) hours in the POCT group versus 28.8 (23.5 to 38.9) hours in the control group, p< 0.0001. Median time to enrolment into other COVID-19 clinical trials was 1.5 (1 to 3) days in the POCT versus 3.0 (2 to 5) days in the control group, p< 0.0001. Sensitivity of the POCT was 99.4% and specificity was 98.3%. The sensitivity of the laboratory PHE reference RdRp assay was 87.2% and specificity was 98.9%. Conclusion: mPOCT was associated with a large reduction in time to results and improvements in infection control measures and patient flow, compared with laboratory PCR. In addition, patients were recruited onto other clinical trials more rapidly with POCT. The QIAstat-Dx SARS-CoV-2 panel had high diagnostic accuracy for the detection of COVID-19 compared to laboratory PCR. Resources should be urgently made available to support the widespread implementation of mPOCT in hospitals, in preparation for the second wave. Disclosures: Tristan William. Clark, BM MRCP DTM&H MD, BioFire Diagnostics (Other Financial or Material Support, Equiptment and consumables for the purposes of research)BioMerieux (Other Financial or Material Support, Equipment and consumables for the purposes of research)Qiagen (Other Financial or Material Support, Discounted Equipment and consumables for the purposes of research)

Text
ofaa439.609 (1) - Version of Record
Download (415kB)

More information

e-pub ahead of print date: 31 December 2020

Identifiers

Local EPrints ID: 450094
URI: http://eprints.soton.ac.uk/id/eprint/450094
PURE UUID: 9d7fdf37-87a4-45c7-8b62-05f9e24e2b0f
ORCID for Nathan J Brendish: ORCID iD orcid.org/0000-0002-9589-4937
ORCID for Sean Ewings: ORCID iD orcid.org/0000-0001-7214-4917
ORCID for Tristan William Clark: ORCID iD orcid.org/0000-0001-6026-5295

Catalogue record

Date deposited: 09 Jul 2021 16:34
Last modified: 07 Sep 2022 01:47

Export record

Altmetrics

Contributors

Author: Nathan J Brendish ORCID iD
Author: Stephen Poole
Author: Vasanth V Naidu
Author: Christopher Mansbridge
Author: Nicholas Norton
Author: Helen Wheeler
Author: Laura Presland
Author: Sean Ewings ORCID iD
Author: Stephen P Kidd
Author: Nick Cortes

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×